Helix Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
Pharmaceuticals; anti-proliferative agents. Helix will pursue a three-pronged attack on fibrosis, blocking key enzymes responsible for cellular proliferation, formation of collagen and production of funtional tissue growth factor-b. The company initially plans to focus on fibrosis resulting from medical or surgical procedures.
You may also be interested in...
Start-Up Previews (03/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Transdermal Drug Delivery: More Than Skin Deep, features profiles of AllTranz, Ocelus, Quinnova and Syntropharma. Plus these Start-Ups Across Health Care: Apnex Medical, Cellular Dynamics, Helix Therapeutics, Presym and Vatrix Medical.
polyGenomics Inc.
PolyGenomics was spun-out of Yale University to develop a genetic amplification technology in the search for genes implicated in psychiatric illnesses.
Oxagen Ltd.
Oxagen's goal is to use large familial clinical groups and sample banks to identify disease genes through agreements with three groups of academic clinical investigators, located throughout Europe.